Rouhollah Vahabpour

Rouhollah Vahabpour

Auto-generated profile, based on publicly available information

Rouhollah Vahabpour

Department of Medical Lab Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2015
Verified
Journal Article
Open access
SNSherko Nasseri
Sherko Nasseri
SMSeyed Hamidreza Monavari
Seyed Hamidreza Monavari
HKHossein Keyvani
Hossein Keyvani
BNBahram Nikkhoo
Bahram Nikkhoo
RRRouhollah Vahabpour Roudsari
Rouhollah Vahabpour Roudsari
MKMohammad Khazeni
Mohammad Khazeni
Background: Human papilloma virus (HPV) infection is one of the most common sexually transmitted diseases that affects men like women and infected cutaneous and mucosal squamous epithelium. The aim of the present study was to determine the prevalence of HPV in the semen of oligospermic, azoospermic and normal patients.

2 October 2024 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
SESaeideh Ebrahimi
Saeideh Ebrahimi
MSMajid Sadeghizadeh
Majid Sadeghizadeh
MAMohammad Reza Aghasadeghi
Mohammad Reza Aghasadeghi
MAMehdi Shafiee Ardestani
Mehdi Shafiee Ardestani
SAShaghayegh Adib Amini
Shaghayegh Adib Amini
RVRoohollah Vahabpour
Roohollah Vahabpour
Nano-drug delivery systems have become a promising approach to overcoming problems such as low solubility and cellular uptake of drugs. Along with various delivery devices, dendrimers are widely used through their unique features. PEG-citrate dendrimers are biocompatible and nontoxic, with the ability to improve drug solubility. Curcumin, a naturally occurring polyphenol, has multiple beneficial properties, such as antiviral activities. However, its optimum potential has been significantly hampered due to its poor water solubility, which leads to reduced bioavailability. So, the present study attempted to address this issue and investigate its antiviral effects against HIV-1. The G2 PEG-citrate dendrimer was synthesized. Then, curcumin was conjugated to it directly. FTIR, HNMR, DLS, and LCMS characterized the structure of products. The conjugate displayed an intense yellow color. In addition, increased aqueous solubility and cell permeability of curcumin were achieved based on flow cytometry results. So, it could be a suitable vehicle for improving the therapeutic applications of curcumin. Moreover, cell toxicity was assessed using XTT method. Ultimately, the SCR HIV system provided an opportunity to evaluate the level of HIV-1 inhibition by the curcumin-dendrimer conjugate using a p24 HIV ELISA kit. The results demonstrated a 50% up to 90% inhibition of HIV proliferation at 12 μm and 60 μm, respectively. Inhibition of HIV-1 at concentrations much lower than CC50 (300 µM) indicates a high potential of curcumin-dendrimer conjugate against this virus. Thereby, curcumin-dendrimer conjugate proves to be a promising tool to use in HIV-1 therapy.

4 July 2015 in Medical Microbiology and Immunology
Verified
Journal Article
Closed access
PDF file
SAShahla Akhgari
Shahla Akhgari
MMMinoo Mohraz
Minoo Mohraz
KAKayhan Azadmanesh
Kayhan Azadmanesh
RVRouhollah Vahabpour
Rouhollah Vahabpour
MKMonireh Kazemimanesh
Monireh Kazemimanesh
ARAmitis Ramezani
Amitis Ramezani

11 October 2019 in Protein & Peptide Letters
Verified
Journal Article
Closed access
PDF file
RVRouhollah Vahabpour
Rouhollah Vahabpour
PBParya Basimi
Parya Basimi
FRFarzin Roohvand
Farzin Roohvand
HAHassan Asadi
Hassan Asadi
GIGholnaz Mokhtari Irani
Gholnaz Mokhtari Irani
ABAzam Bolhassani
Azam Bolhassani
Background: Supercharged GFP proteins were known as effective carriers for delivery of macromolecules into eukaryotic cells as well as fluorescent fusion tags for in vitro and in vivo detection. Objective: Herein, anti-viral effects of +36 GFP and its anti-tumor effects were studied in vitro and in vivo, respectively. Method: We evaluated anti-HIV, anti-HSV, and anti-HCV effects of +36 GFP in vitro using ELISA, and real time PCR as common techniques for their detection, respectively. Moreover, we assessed the role of +36 GFP for eliciting HPV-related anti-tumor effects in mice due to the lack of HPV replication in vitro. Results: Our data showed that +36 GFP efficiently enter the cells and augment the transfection rate of HPV16E7 antigen, as well. Furthermore, +36 GFP significantly reduced HCV, HIV and HSV replication up to 75%, 49% and 43% in HCV-infected Huh7.5 cells, HIV-infected Hela cells and HSV-infected Vero cells, respectively. On the other hand, mice immunization with +36 GFP complexed with HPV16 E7 antigen (+36GFP + E7) or fused to HPV16 E7 antigen (+36GFP-E7) elicited a higher Th1 cellular immune response with the predominant IgG2a, IgG2b, IFN-γ and Granzyme B levels than those induced by other groups. These regimens protected mice against TC-1 tumor challenge (~ 67%) compared to E7 protein alone (~ 33%). These data suggested that +36 GFP can act as an anti-viral agent at certain dose due to its high efficiency in cell penetration in vitro and in vivo. Conclusion: Generally, +36 GFP targets viral replication in vitro as well as helps to suppress the growth of HPV-related tumors in vivo.

17 May 2022 in Iranian Journal of Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
MAMehrdad Alemi
Mehrdad Alemi
FKFatemeh Kamali
Fatemeh Kamali
RRRouhollah Vahabpour Roudsari
Rouhollah Vahabpour Roudsari
ZHZahra Hajimahdi
Zahra Hajimahdi
AZAfshin Zarghi
Afshin Zarghi
Background: The development of a highly safe and potent scaffold is a significant challenge in anti-HIV drug discovery. Objectives: This study aimed at developing a novel series of anti-HIV agents based on HIV integrase inhibitor pharmacophores. Methods: A novel series of 8-methyl-4-oxo-1,4-dihydroquinoline-3-carbohydrazide derivatives featuring various substituted benzoyl and N-phenyl carboxamide and carbothioamide moieties were designed and synthesized. Results: According to the biological evaluation, all the developed compounds were effective against HIV at concentrations lower than 150 µM, associated with no significant cytotoxicity (CC50 > 500 µM). Conclusions: Compound 8b, possessing a 4-fluorobenzoyl group, was the most potent compound, with an EC50 of 75 µM. Docking studies revealed that the binding modes of designed compounds are similar to the known HIV integrase inhibitors.